NHC
DFTX

Nicholas Hoffman & Company’s Definium Therapeutics DFTX Stock Holding History

Nicholas Hoffman & Company’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-707
Closed -$7K – 262
2022
Q2 		$7K Buy
+707
New +$8.95K ﹤0.01% 260

Other funds holding DFTX

DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Nicholas Hoffman & Company's DFTX Position: Q3 2022 in Review

Nicholas Hoffman & Company sold out of Definium Therapeutics (DFTX) in Q3 2022, closing a stake of 707 shares — an estimated $7K sold.

Nicholas Hoffman & Company first reported a position in DFTX in Q2 2022 and held it in 1 quarter. The position peaked at $7K in Q2 2022. 101 funds tracked by Wall St. Rank hold DFTX as of Q3 2022.

  • Nicholas Hoffman & Company reported no remaining Definium Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Nicholas Hoffman & Company sold 707 Definium Therapeutics shares in Q3 2022, an estimated $7K.
  • Nicholas Hoffman & Company first reported a position in Definium Therapeutics in Q2 2022 and held it in 1 quarter.
  • Nicholas Hoffman & Company's Definium Therapeutics position peaked at $7K in Q2 2022.
  • 101 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2022.

Based on Nicholas Hoffman & Company's 13F filing for Q3 2022, filed 4 Nov 2022.